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ABSTRACT
Objective: To evaluate the efficacy of Calendula officinalis in relation to Essential Fatty 
Acids for the prevention and treatment of radiodermatitis. Method: This is a randomized 
double-blind controlled clinical trial with 51 patients with head and neck cancer in 
radiotherapy treatment divided into two groups: control (27) and experimental (24). 
Results: There is statistically significant evidence (p-value = 0.0120) that the proportion 
of radiodermatitis grade 2 in Essential Fatty Acids group is higher than Calendula group. 
Through the Kaplan-Meier survival curve we observed that Essential Fatty Acids group 
has always remained below the Calendula group survival curve, due to the lower risk of 
developing radiodermatitis grade 1, which makes the usage of Calendula more effective, 
with statistical significance (p-value = 0.00402). Conclusion: Calendula showed better 
therapeutic response than the Essential Fatty Acids in the prevention and treatment of 
radiodermatitis.
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INTRODUCTION
One of the most common adverse effects of radiothera-
py is the radiodermatitis, skin reactions limited to the treat-
ment field or to its endpoint. Radiodermatitis is defined 
as a group of skin lesions caused by excessive exposure to 
ionizing radiation, which may lead to dehydration of the 
skin, sometimes causing serious complications (ulceration, 
local infection)(1-3).
In patients with head and neck cancer, due to the loca-
tion of the treatment field, radiodermatitis is more com-
monly developed because the skin site is the more sensitive 
and has more skinfolds, causing constant friction and mois-
ture. These are patients who also have an unfavorable nutri-
tional status, having little fat tissue in the irradiated region, 
resulting in greater skin fragility. Often, these patients also 
perform concomitant treatment to chemotherapy, which 
enhances this adverse effect(3-4).
The decision on what to use to minimize the develop-
ment of radiodermatitis in patients will depend on the de-
gree of skin toxicity, nurse’s evaluation and applicability of 
each product. There are some recommendations for inter-
ventions and/or products for the prevention and treatment 
of radiodermatitis, such as: compresses with chamomile tea 
or filtered water, lotion based on essential fatty acid (EFA) 
or unsaturated fatty acid (UFA), Aloe Vera, extrafine hydro-
colloid plate, among others(5).
One of the recommended products, in both the preven-
tion and treatment of radiodermatitis grades 1 to 4, is the 
essential fatty acid (EFA)(5-6), which is the standard product 
for the nursing staff of the institution of this research for the 
prevention and treatment of these skin lesions.
Some studies indicate other therapeutic modalities, one 
of them is the usage of Calendula officinalis (phytotherapy) 
due to its clinical actions(1,5). This is a medicinal plant that 
has the following properties: antiseptic, bactericidal, fun-
gistatic, virucidal, antiulcerative, antiphlogistic, antiallergic, 
restorative properties for skins that are difficult to heal, an-
tiedema, soothing and refreshing for sensitive skin(5,7). It is 
recommended for use in the prevention of dermatitis and 
radiodermatitis(8). The use of Calendula topically for anti-
inflammatory and healing therapeutic actions is suggested 
by the Brazilian National Health Surveillance Agency 
(ANVISA) (9).
Thus, the objective was to evaluate the efficacy of Calen-
dula officinalis comparing to essential fatty acids (EFA) in 
the prevention and treatment of radiodermatitis in patients 
with head and neck cancer, based on toxicity criteria of the 
Radiation Therapy Oncology Group (RTOG).
The choice of these two products (EFA and Calendula) 
is justified because both are allowed and indicated for this 
type of skin lesion(1,5-6,8-9). However, there are incipient stud-
ies based on scientific evidence indicating nursing care and/
or products to be used in the prevention and/or treatment 
of radiodermatitis, uncomfortable and painful adverse ef-
fects to the patient(2). Thus, it is emphasized that the rel-
evance of this research lies in the scarcity of randomized 
controlled trials in the nursing area of cancer, which are 
essential for implementing a secure, efficient and quality 
care to the patient.
METHODS
The research was approved by the Research Ethics 
Committee (REC) of the hospital under protocol CAAE 
0043.0.088.000-11. All participants signed the Consent 
Form (CF) prior to their inclusion in the study.
This is a randomized double blind controlled clinical tri-
al conducted in Radiotherapy department of a philanthrop-
ic hospital specialized in oncology in the city of Curitiba 
located in the state of Parana. The hospital attends adult 
and pediatric patients with cancer. Data were collected from 
October 2011 to May 2012. The recruitment and selection 
occurred through a computerized system of the hospital.
The study included patients of both sexes, aged over 18 
years, diagnosed with head and neck cancer, from the first 
day of radiotherapy session (new cases) and who agreed 
to participate in the research. We excluded those who had 
tumor wounds in the head and neck, previous history of 
radiotherapy in the same treatment field, or previous reports 
of allergic reaction in the use of one of the research products 
(EFA or Calendula).
We excluded participants who used any other product 
on the skin at the treatment site at any time of the study 
and had an allergic reaction to the products or had deficits 
to adhere to the research intervention and follow-up of the 
study recommendations. The compounding pharmacy was 
responsible for the manufacture of both products, absolute 
secrecy of records was maintained, as well as the identifica-
tion number and the product contained in the bottles. The 
bottles were identical, as well as the presentation of both 
products (oil). The product had the following components: 
EFA - sunflower oil, 1% vitamin A, 0.2% vitamin E and 5% 
caprylic acid and Calendula - 4% Calendula oil, 1% vitamin 
A and liquid vaseline.
The filling of bottles in pharmacy was random, yet at 
the same rate for both groups, and the researchers did not 
have access to this information. The bottles were sent to the 
researchers identified only by numbers, so that the study 
could be characterized as double-blind. Only after the data 
analysis the researchers had the numbers of bottles with 
their products contained within them.
Patients who met the eligibility criteria were random-
ized to compose one of the two research groups: experimen-
tal group (Calendula) and control group (EFA). Random-
ization was as follows: when participants entered the study 
they received their number, which occurred in ascending 
order; the distribution sequence of numbered bottles con-
taining the product was previously generated by Microsoft 
Excel software, ensuring a random sample between the ex-
perimental and control groups. The number of bottles pro-
duced by compounding pharmacy was identical to the total 
number of research participants.
Participants applied EFA (control) or Calendula (ex-
perimental) topically in the prevention and treatment of 
radiodermatitis, as described in the research protocol: mode 
of application - application to the skin with a gauze soaked 
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with the product of research in all treatment field every 12 
hours (twice/day), from the first to the last day of radio-
therapy session; first application - hospital: conducted by 
the research collaborator - average of 10 ml/application; 
during application, study participant and/or family mem-
ber/caregiver were advised on how to proceed with the use 
of the product in the household; subsequent applications - 
hospital: applications were made daily by the research team 
or staff nurse, always after each session of radiotherapy; 
household: were carried out by the study participant and/
or family member/caregiver 12 hours after application in 
the hospital.
The primary outcome was the development of radioder-
matitis, assessed by the toxicity grade, according to the cri-
teria of the Radiation Therapy Oncology Group (RTOG): 
Grade 0 - no reaction, intact skin; Grade 1 - mild erythema, 
epilation and/or dry desquamation; Grade 2 - painful ery-
thema, local moist desquamation and/or moderate edema; 
Grade 3 - confluent moist desquamation and/or severe ede-
ma; and Grade 4 - ulcerations, bleeding and/or necrosis(3). 
The participant’s skin in the irradiation field was evaluated 
in the first radiotherapy session, every five sessions and 30 
days after the end of treatment. The evaluation of skin toxic-
ity was performed by a team of trained researchers.
We conducted a pilot test in 30 days, which had 16 par-
ticipants, allowing the sample calculation of 66 patients, 33 
in each group, considering a minimum difference of 30% 
between groups, statistical power of 80% and significance 
level of 5%.
The two groups (experimental and control) were com-
pared according to the clinical, socioeconomic, demograph-
ic and outcome (univariate analysis). Chi-square, Fisher 
and G Williams tests in categorical variables were used. 
For quantitative variables we used U Mann-Whitney and 
Wilcoxon tests.
Survival analysis: Data were censored in the occur-
rence of one of the following facts: Using any other type 
of product into the skin at the treatment site at any time of 
the study, deficit in compliance with the intervention and 
following-up the study orientations, abandon the study or 
death. Survival time was calculated as the interval between 
the dates of treatment baseline to the date of grade 1 radio-
dermatitis development. Survival curves were estimated by 
Kaplan-Meier method without stratification. To compare 
the survival curves we used the Mantel-Haenzel test (log-
rank). For data analysis and survival charts we used Bioe-
stat® and R 2.5.0 softwares. For all tests, 5% significance 
level was adopted.
RESULTS
We included 51 participants in the study, 27 of them 
were allocated to EFA group and 24 to the Calendula group, 
as shown in Figure 1. The number estimated by sample size 
calculation was not reached, but the data collection period 
was terminated due to research schedule.
Most participants were male, white, married, with el-
ementary education, family income 1-2 minimum wages 
and covered by the Brazilian Unified Health System (SUS). 
EFA group had an average age of 60.44 ± 10.53 and the Ca-
lendula group an average age of 62.38 ± 12.71. With regard 
to the profession/occupation, we highlight in EFA group, 
there were seven (25.93%) farmers and four (14.81%) driv-
ers; in Calendula group, there were six (25%) farmers and 
five (20.83%) salesmen/businessman. Most of the partici-
pants of EFA and Calendula groups presented history of 
smoking, alcohol use and sun exposure.
51 participants
27 participants
control group:
EFA
24 participants
Exp. group:
Calendula
13 followed-up
until the end of
treatment
14 withdrawals*
14 followed-up
until the end of
treatment
10 withdrawals*
Figure 1 – Participants` flowchart of randomized controlled clini-
cal trial. Curitiba/PR – 2011-2012.
*The causes of participants` withdrawals by the end of radiotherapy in EFA group 
were: nine due to the use of another product on the skin at the treatment field; two 
withdrawals were due to non-agreement with the the consent forms, two deaths 
and one deficit in compliance to the intervention; Calendula group: Five used other 
product on the skin at the treatment field, and three withdrawals were due to non-
agreement with the consent forms and two deaths.
With regard to clinical diagnosis, there was a predomi-
nance of laryngeal cancer (33.33%), followed by pharyn-
geal cancer (25.93%), in the EFA Group; in the Calendula 
Group, larynx and pharynx cancers had the same incidence, 
presenting seven (29.17%) cases each. In the radiotherapy 
treatment, there was a predominance of concomitant che-
motherapy in EFA group (51.85%) and Calendula group 
(54.17%), as observed in treating with Cobalt-60 (power of 
1.25 MeV) in both groups (EFA = 88.89% and Calendula 
83.33%). EFA group had an average of 36.11 ± 1.78 ses-
sions and the Calendula group an average of 35.67 ± 2.91 
sessions. The radiation doses on EFA group averaged 438.1 
± 6977.04 centigray and in Calendula group an average of 
6812.5 ± 459.9 centigray. Regarding diet, participants were 
fed orally in 92.59% in EFA group and 70.83% in Calendu-
la group. Thus, we emphasize the similarities of the groups 
and their potential comparison.
We observe in Table 1 the data for the assessment of skin 
(toxicity grade) according to the criteria of the RTOG(3), 
every 5 sessions, from baseline to end of treatment and 30 
days later. From the 1st to the 5th session of radiotherapy 
none of the participants developed radiodermatitis in EFA 
and Calendula groups, as well as grade 4, i.e., the maximum 
grade of radiodermatitis was not observed in participants 
throughout treatment. No interruption of treatment oc-
curred due to the development of radiodermatitis grade.
Radiodermatitis was developed from the 10th session 
of radiotherapy, a small number of patients had grade 1 
(EFA = 11.11% and Calendula = 8.33%). At the 15th ses-
sion, most of the participants had no radiodermatitis (EFA 
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= 59.26% and Calendula = 70.83%), but in the EFA group 
40.74% of participants had grade 1. In the 20th session, the 
participants (EFA = 70.37% and Calendula = 66.67%) had 
grade 1 radiodermatitis and both groups showed a small 
number of radiodermatitis grade 2 (EFA = 7.41% and Ca-
lendula = 8.33%). At the 25th session, remained the high-
est incidence of radiodermatitis grade 1 in EFA group 
(65.22%) and Calendula (63.64%), followed by grade 2 in 
EFA group (34.78%) and grade 2 and grade 3 in Calendula 
group (13.64% each).
compared to the Calendula group. Radiodermatitis grade 1 
was more frequent in the 35th session and at the last treat-
ment session (EFA = 57.14% and Calendula = 55.56%). 
In the last session, EFA Group presented higher incidence 
of grades 2 and 3 (46.15%) compared to Calendula group 
(21.43%). In the assessment performed 30 days after the 
end of treatment, most of the participants had no radioder-
matitis, and one (10%) in the EFA group had grade 2 and 
one (8.33%) in the Calendula group had grade 1.
In Table 2 it is observed the period of greatest inci-
dence of development of radiodermatitis, which occurred 
between 15th-25th sessions in both groups (EFA = 88.89% 
and Calendula = 87.50%). EFA and Calendula groups 
showed peak incidence at the 20th session of treatment, 
showing, respectively, 10 (37.04%) and 11 (45.83%) par-
ticipants with radiodermatitis.
With regard to the maximum radiodermatitis grade de-
velopment, we highlight that in EFA group grades 1 and 
2 were similar, showing respectively 44.44% and 40.74%. 
In Calendula group, most participants had grade 1, with a 
significant percentage of 62.50% (Table 2).
Table 1 – Development of radiodermatitis in the participants of 
EFA and Calendula groups from baseline to end of treatment – 
Curitiba, PR, 2011-2012.
Radiodermatitis EFA Group 
(n=27)
Calendula 
Group (n=24)Sessions of radiotherapy
n % n %
10th session
Grade 0
Grade 1
Total
24
3
27
88.89
11.11
100
22 
2
24
91.67
8.33
100
15th session
Grade 0
Grade 1
Grade 2
Total
16
11
0
27
59.26
40.74
0
100
17
6
1
24
70.83
25
4.17
100
20th session
Grade 0
Grade 1
Grade 2
Total
6
19
2
27
22.22
70.37
7.41
100
6
16 
2
24
25
66.67
8.33
100
25th session
Grade 0
Grade 1
Grade 2
Grade 3
Total
0
15
8
0
23
0
65.22
34.78
0
100
2
14
3
3
22
9.09
63.64
13.64
13.64
100
30th session
Grade 0
Grade 1
Grade 2
Grade 3
Total
0
7
6
4
17
0
41.18
32.29
23.53
100
2
10
3
2
17
11.76
58.82
17.65
11.76
100
35th session
Grade 0
Grade 1
Grade 2
Grade 3
Total
0
4
1
2
7
0
57.14
14.29
28.57
100
2
5
0
2
9
22.22
55.56
0
22.22
100
Last session
Grade 0
Grade 1
Grade 2
Grade 3
Total
1
6
3
3
13
7.69
46.15
23.08
23.08
100
3
8
1
2
14
21.43
57.14
7.14
14.29
100
30 days after the treatment period
Grade 0
Grade 1
Grade 2
Total
No aderence
9
0
1
10
3
90
0
10
100
23.08
11
1
0
12
2
91.67
8.33
0
100
14.29
p-values were not statistically significant.
Table 2 – Period of radiodermatitis development grade of toxicity 
in EFA and Calendula groups – Curitiba, PR, 2011-2012.
Radiodermatitis
EFA group
(n=27)
Calendula group
(n=24) p-value
n (%) n (%)
Period for the development of radiodermatitis
10 sessions
15 sessions
20 sessions
25 sessions
30 sessions
3 (11.11)
8 (29.63)
10 (37.04)
6 (22.22)
0 (0)
2 (8.33)
5 (20.83)
11 (45.83)
5 (20.83)
1 (4.17)
p=0.9535
Highest development of radiodermatitis grade (RTOG)
1
2
3
12 (44.44)
11 (40.74)
4 (14.81)
15 (62.50)
3 (12.50)
6 (25)
p=0.1592
p-values were not statistically significant – Williams G-test.
In the 30th session, radiodermatitis grade in the partici-
pants ranged from 0 to 3, the most frequent grade was 1 
in both groups (EFA = 41.18% and Calendula = 58.82%), 
however, the percentage of grade 2 and 3 in EFA was higher 
After specifically analysis of the radiodermatitis grades 
between groups, we observed that there was statistically 
significant evidence (p-value= 0.0120) as the proportion of 
radiodermatitis grade 2 in EFA group is higher than the 
proportion in the Calendula group.
We highlight the prevalence of concomitant radiother-
apy treatment with chemotherapy in both study groups. 
Thus, to assess time to the development of radiodermatitis, 
only participants who underwent concurrent chemotherapy 
(enhancer of radiodermatitis)(3-4), the period of higher in-
cidence was during the 15th to the 20th session, EFA group 
(71.42%), and in the 20th session in the Calendula group 
(53.85%). When checking the radiodermatitis grade in the 
participants, we observed that grade 2 had become more 
frequent in EFA group (57.14%) and grade 1 in Calen-
dula group (61.54%). The maximum radiodermatitis grade 
in participants who underwent concomitant chemotherapy 
with radiotherapy showed significant statistical difference 
between the EFA and Calendula groups (p-value = 0.0179).
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Conducting Kaplan-Meier curve, we observed that the 
median survival time of the participants in EFA group is 
equal to 20 days, around the 20th treatment session is the 
minimum time in which we expect 50% of treated partici-
pants present radiodermatitis grade 1. Since the median 
survival time of the participants of Calendula group is equal 
to 25 days, or approximately at the 25th session of treatment 
is the minimum time in which it is expected 50% of treated 
patients present radiodermatitis grade 1 (Figure 2).
We highlight that EFA group survival curve remains 
always below the Calendula group survival curve. Thus, the 
risk for radiodermatitis grade 1 is greater for the EFA group 
than Calendula group at every point of the trajectory (p-
value = 0.00402) (Figure 2).
DISCUSSION
Studies show that radiodermatitis usually develop after 
the second week of treatment(3). This fact was confirmed in 
this study, in which radiodermatitis was developed from the 
10th session of treatment in both groups as grade 1. Thus, as 
radiotherapy goes on, increased skin toxicity is common as 
observed in the present study results.
At the 15th session of treatment, the EFA group had 11 
(40.74%) participants with radiodermatitis grade 1, while 
the Calendula group had almost twice as many participants 
with the same toxicity grade (25%). Through this, Calen-
dula group prevented more effectively the development of 
radiodermatitis compared to EFA group. In the 20th session, 
most of the participants showed radiodermatitis grade 1, 
as well as in the same period began the development of 
radiodermatitis grade 2 in both groups.
At the 25th session EFA group presented all participants 
with grade 1 (65.22%) or grade 2 (34.78%) of radioder-
matitis. Calendula group presented radiodermatitis grade 0 
(9.09%) grade 1 (63.64%) grade 2 (13.64%) and grade 3 
(13.64%), in other words, the latter group had a greater va-
riety of skin toxicity. Thus, both groups had substantially 
the same radiodermatitis grade 1; grade 2 remained more 
incident in EFA group. We emphasize that there were par-
ticipants in the Calendula group who still had no signs of 
radiodermatitis during the treatment period.
At the 30th session, the radiodermatitis grade of the par-
ticipants in both groups ranged from 0 to 3. Comparing 
the two groups, we noted that only the Calendula group 
had participants without radiodermatitis (11.76%); grade 
1 were more prevalent in both groups (EFA = 41.18% and 
Calendula = 58.82%), however, with a higher percentage 
in Calendula group; radiodermatitis grade 2 and grade 3 
had exactly twice as many participants in EFA group when 
compared to Calendula group. Therefore, Calendula group 
best prevents the radiodermatitis development when com-
pared to EFA group, Calendula group had lower skin toxic-
ity grades.
At the 35th session of treatment the Calendula group 
also had two (22.22%) participants without radiodermatitis 
and two (22.22%) participants grade 3, with prevalence of 
grade 1 (55.56%). On the other hand, the EFA group pre-
sented grade 1-3, being more frequent grade 1 (57.14%).
In the last treatment session EFA group presented 
higher incidence in grade 2 and grade 3 (46.15%) com-
pared to Calendula group (21.43%). Calendula group had 
3 participants with radiodermatitis grade 0 (21.43%) and 
had the highest rate of radiodermatitis grade 1 (57.14%). 
This reinforces previous findings that Calendula prevents 
the development of radiodermatitis and decreases the toxic-
ity of the treatment.
In the assessment performed 30 days after the end of 
treatment, the majority of participants’ (EFA = 90% and 
Calendula = 91.67%) radiodermatitis were not developed, a 
fact that corroborates to other author’s information(2), which 
showed that about six weeks after the treatment the skin 
reactions, except the most serious, were healed. In the EFA 
group 10% had grade 2 and in the Calendula group 8.33% 
had grade 1 in this period. This difference in toxicity grades 
between the groups may be related to the therapeutic re-
sponse to the products.
In the overall analysis, the period of greatest frequency 
of radiodermatitis occurred from the 15th to the 25th radio-
therapy session, in both groups, with the peak incidence at 
the 20th session. EFA group began developing radioderma-
titis prior to the Calendula group. In relation to the maxi-
mum radiodermatitis grade developed by the participants, 
we observed that EFA group had almost the same percent-
age of grade 1 (44.44%) and grade 2 (40.74%). On the other 
hand, the highest incidence in the Calendula group was 
grade 1 (62.50%), however, this group also had the greatest 
number of participants with radiodermatitis grade 3 (25%) 
when compared to the EFA group (14.81%).
The development of radiodermatitis grade 1 and 3 
showed no significant statistical difference between treat-
ments with EFA and Calendula. However, there was sta-
tistically significant evidence (p-value = 0.0120) for the 
radiodermatitis grade 2, EFA group had a higher incidence 
of this grade than Calendula group, that is, Calendula was 
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Figure 2 – Kaplan-Meier curve comparing the time to event of 
radiodermatitis of EFA and Calendula groups. Curitiba/PR – 2011-
2012.
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significantly more effective than EFA to prevent the devel-
opment of radiodermatitis grade 2.
Regarding the concomitant radiotherapy and chemo-
therapy treatments, which was observed in over 50% of 
participants in both groups, some studies(3-4) indicate that 
these patients are more likely to develop radiodermatitis, 
that is, this adverse effect is amplified. In the results of these 
participants, radiodermatitis in EFA Group had a higher 
incidence from the 15th to the 20th session (71.42%) of treat-
ment while most of the participants of Calendula group 
presented radiodermatitis on the 20th session (53.85%). 
Thus, EFA group developed radiodermatitis before Calen-
dula group in concomitant treatment of participants.
Considering the isolated analysis of participants who 
underwent concomitant treatment, the maximum develop-
ment of radiodermatitis grade presented was different be-
tween the two groups. Grade 2 was more frequent in the 
EFA group (57.14%) and grade 1 was more frequent in the 
Calendula group (61.54%). We highlight that the toxicity 
grade of the skin was statistically different between groups 
(p = 0.0179). Thus, most participants of Calendula group 
showed the lowest radiodermatitis grades, that is, Calendula 
was significantly more effective than EFA in relation to the 
maximum grade of skin toxicity.
In a blind randomized controlled clinical trial of 357 
patients with head and neck, breast and anorectal cancer 
undergoing radiotherapy treatment, it was found that pa-
tients who were concomitantly treated with chemotherapy 
had significantly worse skin reactions, both subjectively 
and objectively (10). As in another randomized controlled 
clinical trial with 506 patients with head and neck cancer 
that showed a higher incidence of this reaction in patients 
concomitantly treated with chemotherapy, supporting the 
current research(11).
From the results presented, Calendula is a protective 
factor for the development of radiodermatitis in patients 
on concomitant treatment with chemotherapy, despite these 
people being at greatest risk for its development, Calendula 
proved to be significantly more effective.
By means of Kaplan-Meier curve, we presented survival 
curve for EFA group , which was always below the Calen-
dula group survival curve due to lower risk of developing ra-
diodermatitis grade 1, which makes the usage of Calendula 
more effective, with statistical significance (p = 0.00402).
The effects of Calendula on the skin are remarkable and 
recognized throughout the world due to its healing activ-
ity(8), which may explain the best therapeutic response in ra-
diodermatitis on the current research. A blind randomized 
study with 254 women undergoing radiotherapy for breast 
cancer compared the usage of calendula (126 patients) with 
Trolamine® (128 patients) and found that the incidence 
of radiodermatitis grade 1 and 2, as well as local pain and 
discontinuation of treatment, were lower in patients who 
had used Calendula(1). This result was presented in other 
studies(12-16), which indicated Calendula as a product with a 
significant protective effect on radiodermatitis.
Through the presented results, we observed that the 
Calendula group achieved better therapeutic responses in 
preventing and/or minimizing the development of radio-
dermatitis and toxicities grades in the skin of patients with 
head and neck cancer compared to the EFA group.
CONCLUSION
Radiodermatitis is one of the most common adverse ef-
fects of radiotherapy, however, it should be prevented, mini-
mized and/or treated by nurses according to recommenda-
tions and/or interventions based on scientific evidence. The 
present study demonstrated the effectiveness of Calendula 
in the prevention and treatment of radiodermatitis in pa-
tients with head and neck cancer. The survival rate during 
radiodermatitis development of patients using the Calendu-
la was higher compared to that of patients using EFA, but 
the sample size may have affected the statistical significance.
The limitations presented in the study refer to disadvan-
tages in the performance of clinical trials, related to the cost, 
because they are expensive; require long time for their de-
velopment and high number of qualified human resources. 
Also, it is worth noting as difficulties: keeping participants 
until the end of the study; constant assessments with the 
participants for a long period of data collection; control 
of confounder variables; and cooperation of other health 
professionals in the clinical trial, which interfere with the 
therapeutic approach researched.
The results of this research collaborate to the profes-
sional nursing practice, providing rationale for an evidence-
based practice; however, the consolidation of more studies 
on the subject is required, as well as its performance with 
a larger number of participants, since scientific evidence 
seems to be incipient and still not enough to support on-
cology nursing and/or recommend the use of products for 
the prevention and/or treatment of radiodermatitis, there is 
a gap of knowledge regarding the subject. Furthermore, we 
emphasize the importance of clinical trials, which are fun-
damental to the achievement of a safe, effective and quality 
care for patients, which should be constantly stimulated by 
the institutions.
RESUMO
Objetivo: Avaliar a eficácia da Calendula officinalis em relação aos Ácidos Graxos Essenciais na prevenção e tratamento de radiodermatite. 
Método: Trata-se de ensaio clínico randomizado duplo cego realizado com 51 pacientes com câncer de cabeça e pescoço em tratamento 
radioterápico divididos em dois grupos: controle (27) e experimental (24). Resultados: Há evidência estatística significativa (p-valor 
= 0,0120) de que a proporção de radiodermatite grau 2 no Grupo Ácidos Graxos Essenciais é superior ao Grupo Calêndula. Por meio 
da curva de Kaplan-Meier observa-se que a sobrevida do Grupo Ácidos Graxos Essenciais manteve-se sempre abaixo da curva de 
sobrevida do Grupo Calêndula, devido ao menor risco de desenvolver radiodermatite grau 1, o que torna a utilização da Calêndula mais 
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eficaz, com significância estatística (p-valor = 0,00402). Conclusão: A Calêndula exibiu melhor resposta terapêutica do que o Ácidos 
Graxos Essenciais na prevenção e tratamento da radiodermatite.
Registro Brasileiro de Ensaios Clínicos: RBR-237v4b.
DESCRITORES
Calêndula; Radiodermatite; Pesquisa em Enfermagem Clínica; Enfermagem Oncológica; Ensaio Clínico.
RESUMEN
Objetivo: Evaluar la eficacia de la Calendula officinalis con respecto a los Ácidos Grasos Esenciales en la prevención y tratamiento 
de radiodermatitis. Método: Se trata de ensayo clínico randomizado doble ciego realizado con 51 pacientes con cáncer de cabeza y 
cuello en tratamiento radioterápico divididos en dos grupos: control (27) y experimental (24). Resultados: Existe evidencia estadística 
significativa (p-valor = 0,0120) de que la proporción de radiodermatitis grado 2 en el Grupo Ácidos Grasos Esenciales es superior al 
Grupo Caléndula. Por medio de la curva de Kaplan-Meier se observa que la supervivencia del Grupo Ácidos Grasos Esenciales se 
mantuvo siempre por debajo de la curva de supervivencia del Grupo Caléndula, en virtud del menor riesgo de desarrollar radiodermatitis 
grado 1, lo que hace la utilización de la Caléndula más efectiva, con significación estadística (p-valor = 0,00402). Conclusión: La 
Caléndula exhibió mejor respuesta terapéutica que los Ácidos Grasos Esenciales en la prevención y tratamiento de la radiodermatitis.
Registro Brasileño de Ensayos Clínicos: RBR-237v4b.
DESCRIPTORES
Calendula; Radiodermatitis; Investigación en Enfermería Clínica; Enfermería Oncológica; Ensayo Clínico.
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